SCHEMBL839726

SCHEMBL839726

CCOC(Sc1ncnc2c1cnn2-c1ccccc1OC)C(=O)Nc1ccon1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GCK P35557 6/20 0.47
ALDH1A1 P00352 5/20 0.44
SMN1; SMN2 Q16637 3/20 0.44
RAB9A P51151 4/20 0.43
SLC2A1 P11166 3/20 0.43
SLC2A3 P11169 3/20 0.43
SLC2A2 P11168 2/20 0.43
S1PR2 O95136 1/20 0.43
MAPT P10636 3/20 0.42
KDM4E B2RXH2 2/20 0.42
RXFP1 Q9HBX9 1/20 0.42
HPGD P15428 1/20 0.41
DYRK3 O43781 1/20 0.41
LCK P06239 1/20 0.41
CSF1R P07333 1/20 0.41
LYN P07948 1/20 0.41
KIT P10721 1/20 0.41
FRK P42685 1/20 0.41
PRKCD Q05655 1/20 0.41
MAPK14 Q16539 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL839071 0.82 ALDH1A1 (0.52) GCKALDH1A1SMN1; SMN2RAB9ASLC2A1
SCHEMBL838792 0.81 GCK (0.62) GCKALDH1A1SMN1; SMN2RAB9ASLC2A1
SCHEMBL838504 0.76 GCK (0.53) GCKALDH1A1SMN1; SMN2RAB9AS1PR2
SCHEMBL837953 0.75 GCK (0.69) GCKALDH1A1SMN1; SMN2RAB9AS1PR2
SCHEMBL837948 0.74 GCK (0.65) GCKALDH1A1SMN1; SMN2RAB9AS1PR2
SCHEMBL838818 0.68 GCK (0.79) GCKKCNH2
SCHEMBL838480 0.67 GCK (0.84) GCKKCNH2
SCHEMBL838853 0.67 GCK (0.84) GCKKCNH2
SCHEMBL6205196 0.66 SLC2A1 (0.65) SMN1; SMN2RAB9ASLC2A1SLC2A3SLC2A2
SCHEMBL838704 0.66 GCK (0.77) GCKKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143263-B2 Therapeutic agents ASTRAZENECA AB (SE) 2012-03-27 US claimed
US-8143263-B2 Therapeutic agents ASTRAZENECA AB (SE) 2012-03-27 US disclosed
US-8143263-B2 Therapeutic agents ASTRAZENECA AB (SE) 2012-03-27 US disclosed
US-8143263-B2 Therapeutic agents ASTRAZENECA AB (SE) 2012-03-27 US disclosed
US-20100093757-A1 THERAPEUTIC AGENTS 414 ASTRAZENECA AB (SE) 2010-04-15 US disclosed
US-20100093757-A1 THERAPEUTIC AGENTS 414 ASTRAZENECA AB (SE) 2010-04-15 US disclosed
US-20100093757-A1 THERAPEUTIC AGENTS 414 ASTRAZENECA AB (SE) 2010-04-15 US disclosed
WO-2010015849-A2 THERAPEUTIC AGENTS 414 ASTRAZENECA AB (SE) 2010-02-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100093757-A1 THERAPEUTIC AGENTS 414 GCK, GCKR, GPR119 GCK 1/4885ALDH1A1 1918/4885SMN1; SMN2 3257/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.